Skip to main content
CARMAT logo

CARMAT — Investor Relations & Filings

Ticker · ALCAR ISIN · FR0010907956 LEI · 969500ARXACM0P0KH333 PA Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2024-05-16 Capital/Financing Update
Country FR France
Listing PA ALCAR

About CARMAT

https://www.carmatsa.com/en/

CARMAT is a medical technology company that designs, develops, and markets the Aeson® total artificial heart. This bioprosthetic device provides a therapeutic solution for patients suffering from end-stage biventricular heart failure. Aeson® is designed to replace the native heart, primarily as a bridge to transplantation for eligible patients. A key feature of the device is its self-regulation capability, which uses embedded sensors and biocompatible materials to automatically adapt blood flow based on the patient's physiological needs, thereby mimicking the function of a natural heart.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces the launch of a fundraising effort ("levée de fonds") aiming to raise approximately 15 M€ through the issuance of new shares. It details the pricing, structure (reserved offering and public offering via PrimaryBid), and the intended use of the proceeds. This content directly relates to the company's financing activities and capital structure changes. Based on the definitions, the most appropriate category is 'Capital/Financing Update' (CAP). The document is a formal announcement detailing the terms of the capital raise, not a general regulatory filing (RNS) or a report publication announcement (RPA), as it contains substantive financial action details.
2024-05-16 French
Modalités de mise à disposition des documents préparatoires à l'AG
AGM Information Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces the details for the upcoming "Assemblée générale mixte" (Combined General Meeting) scheduled for May 30, 2024. It informs shareholders about the availability of preparatory documents and the modalities for participation and voting (in person, by proxy, or by correspondence). This content directly relates to the logistics and materials surrounding a shareholder meeting, which aligns perfectly with the definition of AGM Information (AGM-R). While it mentions documents being made available, the primary focus is the meeting itself and the associated procedures, making AGM-R more specific than a general Report Publication Announcement (RPA).
2024-05-07 French
Inside Information / Other news releases
Earnings Release Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and provides an update on clinical study progress (EFICAS study), reiterates the 2024 outlook (sales forecast), and mentions short-term financial support from shareholders. This structure—a brief announcement summarizing key operational and financial highlights for a specific period (or update) without the full detail of a quarterly or annual report—is characteristic of an Earnings Release (ER). It is not a full Annual Report (10-K) or an Interim Report (IR), nor is it a transcript (CT) or a formal presentation (IP). It is a direct announcement of results and outlook. FY 2024
2024-05-06 English
Informations privilégiées / Autres communiqués
Earnings Release Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and provides an update on the EFICAS clinical trial progress, reiterates 2024 revenue guidance (14 M€), and discusses short-term financing needs and confirmation from reference shareholders. This content structure—a formal announcement of operational and financial highlights, often released outside of mandatory quarterly/annual filings—is characteristic of an Earnings Release (ER) or a general corporate update. Since it provides key financial guidance and operational milestones rather than the full, detailed financial statements of a quarterly report (IR) or annual report (10-K), 'ER' is the most appropriate classification. It is not a transcript (CT), a presentation (IP), or a simple notice of dividend (DIV). FY 2024
2024-05-06 French
Modification des droits attachés aux catégories d'actions
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a formal declaration dated May 3, 2024, titled 'Information relative au nombre total de droits de vote et d'actions composant le capital social' (Information relative to the total number of voting rights and shares comprising the share capital). It explicitly references Article 223-16 of the General Regulation of the Autorité des marchés financiers (AMF), which mandates disclosure of the total number of shares and voting rights. This type of filing, detailing the total share capital and voting rights as of a specific date (April 30, 2024), is a mandatory regulatory disclosure in France. While it relates to capital structure, it is not a financing announcement (CAP) or a share issue announcement (SHA) in the sense of a primary offering or buyback, but rather a periodic statutory disclosure of the current capital base. This specific type of mandatory periodic disclosure regarding share capital and voting rights, especially when referencing specific regulatory articles, often falls under general regulatory filings or specific capital structure updates. Given the options, it is a specific regulatory disclosure about the capital structure. Since there is no specific code for 'Total Voting Rights Disclosure', and it is a formal regulatory filing detailing capital structure components (shares and voting rights), it is best classified as a general Regulatory Filing (RNS) or potentially related to Share Issue/Capital Change (SHA) if the context implies a recent change, but RNS is the safer fallback for specific, non-standard regulatory reports. However, since it is a direct report on the composition of the capital and voting rights, which is a fundamental aspect of share structure, and not just an announcement of a transaction, I will check if it fits better elsewhere. It is not a dividend notice (DIV), director dealing (DIRS), or earnings release (ER). Given the nature of mandatory periodic disclosure of voting rights, RNS is the most appropriate general regulatory category if a more specific one is unavailable. I will use RNS as the best fit for a mandatory, periodic regulatory disclosure not covered by other specific codes.
2024-05-03 French
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and its main purpose is to announce the availability of the "Document d'enregistrement universel 2023" (Universal Registration Document 2023). It explicitly states that the document was filed with the AMF (Autorité des Marchés Financiers) and is now available to the public. The content is a brief announcement describing *where* to find the full annual report and related governance/financial information, rather than being the full report itself. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating a report has been published points towards a Report Publication Announcement (RPA). The document is short (6302 chars) and serves primarily to announce the publication of the larger annual filing (which contains the 10-K equivalent information).
2024-04-30 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.